首页> 外文期刊>Cancer biotherapy and radiopharmaceuticals >Update: molecular radiotherapy: survey and current status.
【24h】

Update: molecular radiotherapy: survey and current status.

机译:更新:分子放射疗法:调查和当前状态。

获取原文
获取原文并翻译 | 示例
       

摘要

Molecular radiotherapy (MRT) is founded on the ability to identify or synthesize radionuclide carriers that recognize and bind to tumor-associated target molecules. Advances in our understanding of the molecular biology of cancer and other diseases have identified molecules and signaling pathways that we can now visualize, in vivo, for diagnosis, staging, and to identify optimal therapy and monitor patient response to therapy. These advances have also helped identify targets for MRT, making it possible to target radiation at the cellular and molecular level. MRT is typically administered systemically, intracavitary, or locoregional administration has also been examined. In contrast to chemotherapy, wherein all proliferating cells are affected, MRT delivers radiation to only those cells that express cancer markers.
机译:分子放射疗法(MRT)建立在识别或合成识别并结合与肿瘤相关的靶分子的放射性核素载体上的能力。我们对癌症和其他疾病的分子生物学的了解的进步已经确定了分子和信号通路,我们现在可以在体内对其进行可视化,以进行诊断,分期,并确定最佳疗法并监测患者对疗法的反应。这些进展也有助于确定MRT的靶标,从而有可能在细胞和分子水平上靶向放射。 MRT通常是全身,腔内或局部给药。与化疗(其中所有增殖细胞都受到影响)相反,MRT仅向表达癌症标志物的细胞提供辐射。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号